Salmeterol/fluticasone propionate in a single inhaler device (SLM/FP) versus theophylline (THEO)+FP in patients with COPD

M. Cazzola, P. Noschese, G. D'Amato, P. Santus, S. Centanni, L. Spicuzza, G. U. Di Maria (Naples, Milan, Catania, Italy)

Source: Annual Congress 2002 - Combination therapies in asthma and COPD
Session: Combination therapies in asthma and COPD
Session type: Poster Discussion
Number: 2393
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
M. Cazzola, P. Noschese, G. D'Amato, P. Santus, S. Centanni, L. Spicuzza, G. U. Di Maria (Naples, Milan, Catania, Italy). Salmeterol/fluticasone propionate in a single inhaler device (SLM/FP) versus theophylline (THEO)+FP in patients with COPD. Eur Respir J 2002; 20: Suppl. 38, 2393

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
A comparison of the efficacy of salmeterol/fluticasone propionate combination (SF) with beclometasone dipropionate (BDP) delivered via metered dose inhaler (MDI) in patients not well controlled on bronchodilators alone
Source: Eur Respir J 2001; 18: Suppl. 33, 53s
Year: 2001

Synergy with salmeterol and fluticasone propionate after administration from a single inhaler (Seretide™)
Source: Eur Respir J 2001; 18: Suppl. 33, 176s
Year: 2001

Lower systemic exposure to corticosteroid for fluticasone propionate/salmeterol (500/50mcg bd) compared to budesonide/formoterol (400/12mcg bd) administered via combination dry powder inhalers in subjects with COPD
Source: Eur Respir J 2006; 28: Suppl. 50, 205s
Year: 2006

Low dose salmeterol/fluticasone propionate combination (SFC) via metered dose inhaler (MDI) improves asthma control and quality of life in patients not well controlled on inhaled steroids (ICS)
Source: Eur Respir J 2002; 20: Suppl. 38, 47s
Year: 2002

Comparison of ciclesonide (MDI) once daily and fluticasone propionate (Diskus®) twice daily in the treatment of patients with moderate asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 666s
Year: 2006

QVAR pMDI is more cost-effective than fluticasone propionate (FP) or CFC-beclometasone dipropionate (BDP) PMDI in a real-life asthmatic population receiving an increase in ICS dose
Source: Annual Congress 2009 - Sustainability in treatment of COPD patients according to economics and quality of care
Year: 2009

Sequential flexible therapy with formoterol (Foradil®) plus budesonide (Miflonide®) versus a fixed combination of salmeterol and fluticasone (Seretide®) in asthma self-management
Source: Eur Respir J 2002; 20: Suppl. 38, 388s
Year: 2002

Salmeterol/fluticasone propionate combination (SFC) versus doubling dose of fluticasone propionate (FP) in children with asthma insufficiently controlled on moderate doses of inhaled corticosteroids
Source: Annual Congress 2010 - Managing asthma and allergic disease in children
Year: 2010


Clinical equivalence of salmeterol/fluticasone propionate combination 50/100mcg b.i.d. delivered via DiskusÔ or CFC-free metered dose Inhaler (MDI) in children with asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 311s
Year: 2003

Efficacy of salmeterol/fluticasone propionate combination administered via Diskus inhaler in children with asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 429s
Year: 2002

Efficacy of combination fluticasone furoate/vilanterol (FF/VI) and salmeterol/fluticasone propionate (SFC) over 12 weeks in patients with COPD
Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights
Year: 2012

Improvements in FEV1 and symptoms in poorly-reversible COPD patients following 24 weeks of treatment with the salmeterol/fluticasone propionate combination 50/500 BID via the Diskus™inhaler
Source: Eur Respir J 2001; 18: Suppl. 33, 176s
Year: 2001

Once-daily versus twice-daily administration of mometasone furoate dry powder inhaler (MF-DPI) improves lung function in children with asthma previously maintained on inhaled corticosteroids (ICS)
Source: Eur Respir J 2004; 24: Suppl. 48, 164s
Year: 2004

Efficacy of salmeterol/fluticasone propionate (50/100mcg/day) delivered via the Diskus™ and MDI in children with asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 311s
Year: 2003

Onset of action of salmeterol/fluticasone (SFC) in single inhaler vs. salmeterol (S) in patients with COPD
Source: Eur Respir J 2003; 22: Suppl. 45, 285s
Year: 2003

Patients’ ability to use a novel fluticasone propionate/formoterol breath-triggered inhaler (BTI) vs. budesonide/formoterol dry powder inhaler (DPI)
Source: International Congress 2018 – Innovative therapies in asthma and COPD
Year: 2018



Single inhaler therapy (SiT) with budesonide/formoterol (BUD/FM) is effective in asthma control
Source: Eur Respir J 2005; 26: Suppl. 49, 124s
Year: 2005

Combination therapy with salmeterol and fluticasone propionate (SFC) is more effective than salmeterol (SAL) alone in reducing exacerbations of COPD
Source: Eur Respir J 2005; 26: Suppl. 49, 292s
Year: 2005

Comparison of HFA salmeterol-fluticasone (SFC) combination when given through breath actuated inhaler (BAI) and pressurised meter dose inhaler (pMDI) in patients with moderate-to-severe asthma
Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics
Year: 2013


Formoterol via turbuhaler (F) versus salbutamol via pressurized metered-dose inhaler (SB) in acute exacerbations of COPD
Source: Eur Respir J 2001; 18: Suppl. 33, 425s
Year: 2001